JP2016521695A5 - - Google Patents

Download PDF

Info

Publication number
JP2016521695A5
JP2016521695A5 JP2016517101A JP2016517101A JP2016521695A5 JP 2016521695 A5 JP2016521695 A5 JP 2016521695A5 JP 2016517101 A JP2016517101 A JP 2016517101A JP 2016517101 A JP2016517101 A JP 2016517101A JP 2016521695 A5 JP2016521695 A5 JP 2016521695A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
fibrosis
och
composition according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016517101A
Other languages
English (en)
Japanese (ja)
Other versions
JP6473938B2 (ja
JP2016521695A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2014/000484 external-priority patent/WO2014194407A1/en
Publication of JP2016521695A publication Critical patent/JP2016521695A/ja
Publication of JP2016521695A5 publication Critical patent/JP2016521695A5/ja
Application granted granted Critical
Publication of JP6473938B2 publication Critical patent/JP6473938B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016517101A 2013-06-05 2014-06-04 抗線維化化合物、その方法および使用 Active JP6473938B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361831404P 2013-06-05 2013-06-05
US61/831,404 2013-06-05
PCT/CA2014/000484 WO2014194407A1 (en) 2013-06-05 2014-06-04 Anti-fibrogenic compounds, methods and uses thereof

Publications (3)

Publication Number Publication Date
JP2016521695A JP2016521695A (ja) 2016-07-25
JP2016521695A5 true JP2016521695A5 (enExample) 2017-07-20
JP6473938B2 JP6473938B2 (ja) 2019-02-27

Family

ID=52007349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016517101A Active JP6473938B2 (ja) 2013-06-05 2014-06-04 抗線維化化合物、その方法および使用

Country Status (14)

Country Link
US (1) US9737523B2 (enExample)
EP (1) EP3003298B1 (enExample)
JP (1) JP6473938B2 (enExample)
KR (1) KR102294405B1 (enExample)
AU (1) AU2014277568B2 (enExample)
CA (1) CA2914261C (enExample)
DK (1) DK3003298T3 (enExample)
ES (1) ES2978920T3 (enExample)
PH (1) PH12015502717B1 (enExample)
PL (1) PL3003298T3 (enExample)
RU (1) RU2726416C2 (enExample)
SG (1) SG11201510003VA (enExample)
WO (1) WO2014194407A1 (enExample)
ZA (1) ZA201600015B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144461A1 (en) 2017-01-31 2018-08-09 The Board Of Regents Of The University Of Oklahoma Animal wound model and methods of use
CN112168822B (zh) * 2020-09-27 2022-11-08 集美大学 犬尿酸在改善高脂饮食致血脂异常、肥胖、肠道菌群混乱中的用途
JP2024517463A (ja) * 2021-05-04 2024-04-22 ソヴィダ ソリューションズ リミテッド ニコチンアミドアデニンジヌクレオチド(nad)組成物、それらの製造方法、及びそれらの使用方法
KR20240004954A (ko) * 2021-05-07 2024-01-11 바치바이오메드 인크. 소분자 화합물을 사용하여 여드름-후 위축성 흉터의 외관을 개선하는 방법 (methods of using a small molecule chemical compound to reduce the appearance of post-acne atrophic scarring)
EP4572737A1 (en) * 2022-09-14 2025-06-25 Birchbiomed Inc. Methods of using a small molecule chemical compound to reduce the appearance of rhytids and wrinkles
US20240189279A1 (en) * 2022-12-11 2024-06-13 The Texas A&M University System Immunomodulatory compositions and methods of use thereof
CN119055650A (zh) * 2024-09-06 2024-12-03 上海市东方医院(同济大学附属东方医院) 犬尿喹啉酸在治疗慢性肝硬化中的应用
PL450606A1 (pl) 2024-12-16 2026-06-22 Uniwersytet Łódzki Zastosowanie tryptofanu lub jego metabolitów ze szlaku kynureninowego w profilaktyce i leczeniu dermatofitoz oraz kompozycja farmaceutyczna do stosowania zewnętrznego

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1369114A1 (en) 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
WO2006053390A1 (en) * 2004-11-17 2006-05-26 Angiogen Pharmaceuticals Pty. Ltd. A method of modulating b cell functioning
HUP0700051A2 (en) * 2007-01-17 2008-09-29 Univ Szegedi Use of kynurenic acid and derivatives there of for treating of gastrointestinal disorders associated with enhanced motility and inflammation
KR20150021071A (ko) * 2012-06-15 2015-02-27 코나리스 리써치 인스티튜트 아게 니코틴산 및/또는 니코틴아미드 및/또는 트립토판을 포함하는 장내 세균총에 유익한 효능을 가진 약학 조성물

Similar Documents

Publication Publication Date Title
JP2011518833A5 (enExample)
JP2013032389A5 (enExample)
JP2019524883A5 (enExample)
JP2024516371A5 (enExample)
JP2015024998A5 (enExample)
JP2018024682A5 (enExample)
JP2016503793A5 (enExample)
JP2018521020A5 (enExample)
RU2015156196A (ru) Антифиброгенные соединения, способы и их применение
JP2010001302A5 (enExample)
JP2013509429A5 (enExample)
JP2012144574A5 (enExample)
JP2018513150A5 (enExample)
JP2016500661A5 (enExample)
JP2012504133A5 (enExample)
JP2013532130A5 (enExample)
JP2014530818A5 (enExample)
JP2016513130A5 (enExample)
JP2013522326A5 (enExample)
JP2019059781A5 (enExample)
JP2014527040A5 (enExample)
JP2015512943A5 (enExample)
JP2016536360A5 (enExample)
JP2016532632A5 (enExample)
JP2015516419A5 (enExample)